Groupe BSH | Biomedical Engineering

Infiplast Biomedical – firstly called Plastics then renamed as BioMedical – is a specialist in white room plastic injection moulding for the medical sector. In the next few years, this sector will be making more use of plastics due to the multitude of benefits:

The optimisation of asepsis rules: Ease of cleaning and decontamination, disposable properties for certain materials.

The development of new treatments, in particular for orphan diseases, kidney diseases, etc.

Improvement in the quality of care: Outpatient surgery,
Fight against nosocomial infections

Development of preventive medicine by diagnosis

Better cost-effectiveness than other materials.

The BSH Group is well situated in Plastic Valley, one of the first European plastics clusters. This business park features a dense network of SME-SMIs, including raw materials suppliers, machine and equipment manufacturers, moulders, transformers, training organisations, research centres and the Plastipolis competitiveness cluster. Working in such a network enables the group to innovate and organise the partnership strategies required for its development.

Infiplast Biomedical quality certifications

Infiplast Biomedical quality certifications
Innovative solutions are born from this innovation process. As an example, the syringe designed and developed by Infiplast Biomedical for Biomatlante, who manufacture and distribute 100% synthetic dual-phase bone substitutes. This company designed an injectable synthetic bone filler material. It needed a specific syringe to be able to inject the dual-phase material (liquid and powder) into the patient.
The syringe had to offer features such as ensuring the homogeneity of the two phases and the sterility of the material during preparation. Together with the Biomatlante project team, the Infiplast Biomedical R&D team optimised the manufacturing process and developed the product design. Lastly, each company's quality department integrated the regulatory requirements in terms of bio-contamination risk right from the design phase.